Zacks Research Has Positive Estimate for Novavax Q2 Earnings

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Investment analysts at Zacks Research lifted their Q2 2025 earnings estimates for shares of Novavax in a note issued to investors on Tuesday, January 28th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will earn $0.44 per share for the quarter, up from their prior forecast of $0.39. The consensus estimate for Novavax's current full-year earnings is ($1.31) per share. Zacks Research also issued estimates for Novavax's Q2 2026 earnings at $0.07 EPS and FY2026 earnings at $0.39 EPS.

Other equities research analysts have also issued research reports about the stock. B. Riley reiterated a "buy" rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, October 16th. Finally, HC Wainwright restated a "buy" rating and set a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $17.83.

Novavax Stock Performance

NASDAQ:NVAX traded down $0.26 on Thursday, hitting $8.43. The stock had a trading volume of 2,296,175 shares, compared to its average volume of 4,851,849. The stock has a market cap of $1.35 billion, a P/E ratio of -3.73, a price-to-earnings-growth ratio of 66.26 and a beta of 2.14. Novavax has a 1 year low of $3.53 and a 1 year high of $23.86. The firm's fifty day simple moving average is $8.83 and its two-hundred day simple moving average is $10.71.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to analysts' expectations of $65.80 million. The company's quarterly revenue was down 54.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.26) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Beirne Wealth Consulting Services LLC boosted its holdings in Novavax by 65.0% in the 4th quarter. Beirne Wealth Consulting Services LLC now owns 16,500 shares of the biopharmaceutical company's stock valued at $133,000 after purchasing an additional 6,500 shares during the period. TigerOak Management L.L.C. bought a new position in Novavax in the 4th quarter valued at $86,000. Rhumbline Advisers boosted its holdings in Novavax by 6.7% in the 4th quarter. Rhumbline Advisers now owns 208,464 shares of the biopharmaceutical company's stock valued at $1,676,000 after purchasing an additional 13,024 shares during the period. TSP Capital Management Group LLC boosted its holdings in Novavax by 0.6% in the 4th quarter. TSP Capital Management Group LLC now owns 1,358,565 shares of the biopharmaceutical company's stock valued at $10,923,000 after purchasing an additional 7,700 shares during the period. Finally, Sargent Investment Group LLC lifted its holdings in shares of Novavax by 24.3% during the 4th quarter. Sargent Investment Group LLC now owns 50,775 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 9,940 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

Insider Transactions at Novavax

In related news, Director James F. Young sold 4,600 shares of the firm's stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total value of $39,008.00. Following the completion of the transaction, the director now directly owns 57,160 shares of the company's stock, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares of the company's stock, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock worth $119,641 in the last quarter. Insiders own 1.00% of the company's stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.